Novartis moved to acquire Pikavation Therapeutics (a Synnovation subsidiary) in a deal valuing the transaction at up to $3 billion, including a $2 billion upfront component for a mutant‑selective PI3Kα program led by SNV4818. Company statements and regulatory filings describe SNV4818 as a pan‑mutant‑selective inhibitor in early clinical testing for HR+/HER2‑ metastatic breast cancer and other solid tumors. Novartis says the mutant‑selective chemistry aims to spare wild‑type PI3Kα, potentially improving tolerability and combination use with endocrine therapy and CDK inhibitors. Synnovation will retain non‑acquired assets, while Novartis takes on global development and commercialization to accelerate SNV4818’s clinical path.